Drug Database
YY

YY-3130 (YY 3130 / YY3130)

✓ Approved

YuYu Pharma · Small Molecule · Small Molecule

What is YY-3130?

YY-3130 is a small molecule developed by YuYu Pharma. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesYY 3130, YY3130
CompanyYuYu Pharma
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, YuYu Pharma

Therapeutic Indications

YY-3130 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved

Related Research Articles

PubMedOncology reports2026-08-28

[Expression of Concern] Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells.

Guo Jing J, Chen Li L, Luo Ning N, Yang Weihong W et al.

Following the publication of the above article, a concerned author drew to the authors' attention that the western blot data showing the TGF β1‑experiments in Fig. 4C and D on p. 3129 for the HO‑8910 and A2780 cell lines were strikingly similar, suggesting that the data in this figure had been assembled incorrectly. In addition, various of the western blots featured in this figure, and also in Fig. 2B on p. 3127, were remarkably similar to data which were subsequently submitted for publication in articles written by different authors at different research institutes to a number of different journals, at least one of which has since been retracted on account of data sharing issues with other papers. The authors have been contacted by the Editorial Office to offer an explanation for the apparent anomalies in the presentation of the western blot data in this paper, and we are awaiting their response. Owing to the fact that the Editorial Office has been made aware of potential issues surrounding the scientific integrity of this paper, we are issuing an Expression of Concern to notify readers of this potential problem while the Editorial Office continues to investigate this matter further. [Oncology Reports 33: 3124‑3130, 2015; DOI: 10.3892/or.2015.3902].

PMID 42663282
Read full article →
PubMedMicroorganisms2026-08-27

Contrasting the Microbial Communities in Rhizosphere and Bulk Soils Across Different Eucommia ulmoides Planting Sites and Their Soil Chemical Driving Mechanisms.

Liu Panfeng P, Wang Huaxiang H, Lin Furong F, Du Hongyan H et al.

Soil multifunctionality (SMF) is a core indicator of plantation soil ecological function, and microbial diversity plays a vital role in sustaining it. However, cross-site rhizosphere and bulk SMF disparities and their microbial driving mechanisms remain unclear in Eucommia ulmoides plantations. Here, we collected rhizosphere and bulk soils from three typical sites (Mengzhou, MZ; Liangyuan, LY; and Yuanyang, YY). Soil chemical properties, extracellular enzymes, microbial alpha diversity, community composition and cross-kingdom network topology were measured. Correlation heatmaps, random forest, Redundancy analysis (RDA) and Partial least path modeling (PLS-PM) were adopted to quantify SMF predictors and regulatory pathways. Rhizosphere soils possessed significantly higher alkaline hydrolyzable nitrogen (AN), available phosphorus (AP) and available potassium (AK) than bulk soils at all sites. LY rhizosphere showed the greatest soil organic carbon (SOC), total potassium (TK), available nutrients and enzyme activities, while YY had higher total nitrogen (TN) and AP, yet the lowest enzyme levels. Rhizosphere bacterial and fungal alpha diversity was consistently higher across locations. SMF varied distinctly by site and compartment: LY had substantially higher SMF than MZ and YY in both rhizosphere and bulk soils, with rhizosphere SMF being consistently greater than bulk values across all sites. The PLS-PM (GOF = 0.70) indicated that soil chemical properties regulated SMF via dual pathways: they directly promoted microbial co-occurrence networks and indirectly modified network structure by altering fungal diversity, while suppressing bacterial diversity. Total effect analysis identified soil chemical properties and microbial co-occurrence networks as the core drivers of SMF variation. This work clarifies that rhizosphere effects and soil chemical properties jointly drive SMF by regulating microbial diversity and co-occurrence networks, offering theoretical guidance for sustainable soil management in E. ulmoides plantations.

PMID 42655197
Read full article →
PubMedTransboundary and emerging diseases2026-08-21

Highly Virulent Getah Virus Subgroup GIII-c Emerging in Pigs in China.

Xiang Zhaoying Z, Wang Xingchen X, Huang Yuchen Y, Gao Xinyu X et al.

Getah virus (GETV) is an emerging mosquito-borne zoonotic alphavirus that poses a threat to multiple animal species, particularly pigs, and carries significant public health implications. Nevertheless, the molecular evolution and pathogenicity of circulating GETV strains in China remain incompletely defined. In this study, three GETV strains were isolated from diseased piglets during concurrent outbreaks on three geographically distinct commercial pig farms in China in August 2025. The isolates shared 99.67%-99.91% genomic nucleotide (nt) identity and were phylogenetically classified into subgroup GⅢ-c. Amino acid sequence alignment against 136 reference strains from the GenBank database identified four substitutions in Nsp1 and Nsp3 that were absent from all reference strains, along with six conserved residues largely concentrated in a distinct subclade formed by the three isolates and five related reference strains. Pathogenicity evaluation using a representative isolate (GETV-YY/2025) in 7-day-old piglets revealed that the infected animals developed severe clinical signs, including fever, diarrhea, ataxia, and hindlimb paralysis, with a high mortality rate of 77.8% (7/9). The strain exhibited broad tissue tropism, with high viral loads detected in pharyngeal and rectal swabs, serum, and multiple visceral organs as early as 1 day postinoculation, accompanied by obvious cerebral vascular congestion and pulmonary hemorrhage. Notably, efficient contact transmission to sentinel piglets was observed, resulting in one fatality among the three contact animals (33.3%). Collectively, these findings characterize the emergence of a highly virulent GETV subgroup GⅢ-c circulating in Chinese pig populations, highlighting its capacity for efficient contact transmission and severe pathogenesis in neonatal pigs. This study provides critical insights into the evolutionary dynamics of GETV and informs the urgent development of prevention and control strategies against this re-emerging veterinary pathogen.

PMID 42626796
Read full article →
PubMedFrontiers in endocrinology2026-08-15

Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?

Burmeister Melissa A MA, Brown Skyler A SA, Greer Jakeem J JJ, Hoggatt Tyler J TJ et al.

Obesity is a chronic, multifactorial disease that has reached epidemic status. The glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) is a key therapeutic target to achieve weight loss and glycemic control in obesity and type 2 diabetes mellitus. Tirzepatide and retatrutide, the latest generation of GLP-1-incorporating multi-agonists, target multiple receptors in complementary systems to achieve marked and sustained weight loss. However, the associated gastrointestinal (GI) side effects (e.g., nausea, vomiting, diarrhea, abdominal pain) that often hinder patient compliance underscore a remaining need for therapies with better tolerability. GEP44, a novel, monomeric, chimeric peptide structurally based on native GLP-1, the GLP-1RA exendin-4 (Ex-4), and the gut-derived hormone peptide YY3-36 (PYY3-36), is an agonist at the GLP-1R and multiple neuropeptide Y (NPY) receptors. This review summarizes the design rationale for GEP44 and preclinical evidence supporting its beneficial metabolic effects and tolerability. Like GLP-1, PYY3-36 is associated with decreased food intake (FI), and co-administration of GLP-1RA and PYY3-36 elicits synergistic food intake (FI)- and body weight (BW)-reducing effects with similar or enhanced blood glucose (BG)-lowering effects. Studies examining the efficacy of GEP44 to promote weight loss and improve glucoregulation in lean vs. diet-induced obese rodents report that peripheral administration generally decreases BW, FI, and insulin resistance and increases EE at equivalent or greater magnitudes than those observed with single GLP-1RAs in a GLP-1R-dependent manner with improved GI tolerability. These beneficial actions reflect GEP44's potential to expand the mechanistic scope of anti-obesity medications.

PMID 42602523
Read full article →
PubMedInternational journal of molecular sciences2026-08-13

Transcriptomic and Metabolomic Insights into Tissue- and Cultivar-Dependent Polysaccharide Accumulation in Anoectochilus roxburghii.

Peng Xiaoqun X, Liu Chao C, Liu Yiping Y, Xie Haiwei H et al.

Polysaccharides are major bioactive constituents and quality-related components of Anoectochilus roxburghii. However, how polysaccharide accumulation varies among cultivars and tissues remains poorly understood. Here, crude polysaccharide content was quantified in leaves and stems of three cultivars, Yuanye (YY), Hongxia (HX), and Jianye (JY), and the underlying molecular basis was investigated using transcriptomics, targeted sugar metabolomics, and integrated transcriptome-metabolome analysis. Stems accumulated significantly higher levels of crude polysaccharides than leaves, whereas cultivar-dependent differences were most pronounced in stems. JY stems showed the highest crude polysaccharide content, reaching 357.81 mg g-1 dry weight. Transcriptomic and metabolomic profiles clearly differentiated the cultivars and tissues. Metabolic differences were concentrated at a limited number of sugar-metabolic nodes, whereas the transcriptome showed extensive transcriptional reprogramming. Integrative analyses consistently implicated starch and sucrose metabolism, precursor-sugar interconversion, nucleotide-sugar biosynthesis, and sugar transport, partitioning, and intracellular allocation in differential polysaccharide accumulation. Glucose and D-fructose emerged as key hub metabolites linking transcriptional variation to sugar-metabolic remodeling. These results suggest that tissue- and cultivar-dependent polysaccharide accumulation is associated with coordinated changes in sucrose turnover, precursor sugar supply, nucleotide-sugar formation, and sugar partitioning, particularly in stems. This study provides molecular evidence for the selection of high-polysaccharide germplasm and quality evaluation of A. roxburghii.

PMID 42589571
Read full article →
PubMedEndocrine reviews2026-08-12

Digestive Hormones and Their Impact on Bariatric and Pharmacologic Weight-Loss Therapies.

Amoyel Maxime M, Carette Claire C, Poghosyan Tigran T, Le Beyec-Le Bihan Johanne J et al.

Obesity is a growing global health challenge associated with major cardiometabolic complications. While bariatric surgery remains the most effective treatment for severe obesity, recent advances in incretin-based pharmacotherapy, multi-receptor agonists, and endoscopic bariatric procedures have substantially expanded therapeutic options. Beyond mechanical restriction, these interventions exert their effects through complex hormonal and neurophysiological mechanisms involving gut-brain signaling, gastric motility, and enteroendocrine adaptations. Gut-derived hormones, including ghrelin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), amylin, and leptin, play a central role in the regulation of hunger, satiation, and satiety by integrating nutrient sensing, vagal afferent signaling, and central hypothalamic pathways. Surgical procedures such as laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass induce profound and durable hormonal remodeling, whereas endoscopic sleeve gastroplasty primarily modulates gastric physiology with more modest and heterogeneous endocrine effects. Intragastric balloons induce a transient delay in gastric emptying and achieve moderate short-term weight loss, although their metabolic and weight-loss effects appear limited in durability. In parallel, GLP-1 receptor agonists and emerging multi-agonist therapies reproduce several post-bariatric hormonal adaptations and achieve clinically meaningful weight loss. In this review, we summarize current knowledge on digestive hormone physiology and provide an updated overview of the hormonal mechanisms underlying pharmacologic, endoscopic, and surgical bariatric interventions, highlighting their respective roles within a continuum of obesity treatment strategies.

PMID 42584007
Read full article →

+4500 more articles available with a free account

Sign up free to view all articles →

Ask about YY-3130